Background & Objective: Hypofractionation has been used in curative setting in breast conservative surgery, but still no adequate information about its application in the adjuvant setting after mastectomy in breast cancer patients. The aim of this trial was to assess the efficacy and toxicity of hypofractionation radiotherapy (40 Gy in 15 fractions) in post mastectomy breast cancer patients and to compare these results with those of post mastectomy patients treated retrospectively by conventional radiotherapy (50 Gy in 25 fractions) as regard overall survival (OS), disease free survival (DFS), locoregional disease free survival (LDFS), and toxicities. Patients & Methods: One hundred post mastectomy breast cancer patients were included into this study, they were divided into 2 groups, the 1st included 50 patients treated prospectively with hypofractionated radiotherapy regimen (40 Gy in 15 fractions), and the 2nd (control group) included 50 patients treated retrospectively with conventionally fractionated radiotherapy regimen (50 Gy in 25 fractions). Results: The 2 year overall survival were 96% & 94% respectively (p = 0.7),
Introduction & Objective
Breast cancer is the most commonly diagnosed cancer worldwide and it is the leading cause of cancer death in women. In 2016, 249,260 women have been diagnosed with breast cancer in the United States of America with 40,890 deaths [1] .
Radiation therapy is a part of treatment in all breast conserving surgeries and for a large percentage of breast cancer patients after mastectomy, and it has been identified to decrease the local recurrence by 70% [2] .
Also, it has a positive effect on overall survival, specifically in patients with a high incidence of loco-regional recurrence [3] .
In spite of the established role of adjuvant radiotherapy, much debate remains about the ideal radiotherapy regimen to use. Several alternative fractionation regimens have recently been assessed and compared with the standard fractionation schedule (25 fractions, 2 Gy each/5 weeks) [4] .
The alternative fractionation schedule that has received the most attention is hypofractionation, in which radiation is delivered using a lower number of fractions of more than 2 Gy each (40 Gy/15 daily fractions of 2.67 Gy to the whole breast, with a boost dose of 15 Gy in 3 Gy fractions) [5] .
The theoretical advantages of hypofractionation include an improvement in cell killing from the increase in fraction size and a reduction in treatment duration. Furthermore, shortening the treatment duration means that more patients can be treated with a limited number of machines, a concern that arises in many countries in which access to radiation therapy is limited [6] .
Many trials have confirmed that, hypofractionated radiotherapy schedules are equivalent to conventionally fractionated radiation of 50 Gy in 25 sessions irrespective of stage or breast surgery [5] [7] , hypofractionated whole breast irradiation is a preferred option in United States of America, Canada and United kingdom because of its low cost and geographical convenience [8] .
Due to these established data, hypofractionation has been used in curative setting in breast conservative surgery, but still no adequate information about its application in the adjuvant setting after mastectomy in breast cancer patients.
At our department, hypofractionated radiotherapy was applied first in late 2013 as an adjuvant treatment after breast conserving surgery in node negative patients, and since then, it was used. Currently, almost all patients needing adjuvant radiotherapy to the chest wall receive hypofractionated regimen (40 Gy in 15 fractions).
The aim of this trial was to assess the efficacy and toxicity of hypofractionation radiotherapy (40 Gy in 15 fractions) in post mastectomy breast cancer patients and to compare these results with those of post mastectomy patients treated retrospectively by conventional radiotherapy (50 Gy in 25 fractions) as regard overall, disease free and loco-regional disease free survival, and toxicities.
Patients and Methods
After acceptance of the Mansoura Faculty of Medicine, institutional research 
Radiation Therapy Techniques
Patients were planned in the supine position over a breast board with arms directed cranially using computerized tomography (CT) simulation, with CT slices of 5 mm thick. Standard two tangential fields were used to treat the breast; an additional supraclavicular field was added if lymph nodes treatment was indicated. All patients were planned by 3D-Conformal radiotherapy (3D-CRT) with ELEKTA Linear Accelerator, and precise treatment planning software.
HFRT group were given 4000 cGy/15 fractions/3 weeks at 267 cGy per fraction, 5 day per week.
The control CFRT group were given 5000 cGy/25 fractions/5 weeks at 200 cGy per fraction, 5 days per week.
The photon energy used in both groups was either 6 MV or 15 MV.
Radiation Toxicity and Its Grading
During the radiation therapy schedule; patients were weekly observed for the acute radiation reactions and it was reported and graded according to the Radiation Therapy Oncology Group (RTOG) toxicity criteria.
After ending radiation schedule, patients were followed up every 2 weeks for one month and then, every month to a minimum of 6-months for late reactions, 
Statistical Analysis
Data was analyzed by SPSS, program statistical package for social science version 16.
To test the normality of data distribution, K-S (Kolmogorov-Smirnov) test was done, only significant data revealed to be nonparametric. However all tested data revealed to be parametric. The description of the data done in form of mean (+/−) SD for quantitative data, while frequency & proportion for qualitative data. The analysis of the data was done to test statistical significant difference between groups. For quantitative data, student t-test was used to compare between two groups. Chi square test was used for qualitative data.
Results
The patients , characteristics were matched in between the two groups. (Table 1 ).
All the patients ended their adjuvant radiotherapy schedule. All patients tolerated radiation treatment well, with no radiotherapy interruption because of toxicity in the 1 st group, while in the 2 nd group, treatment was interrupted for 3 patients (for 4 -6 days) because of G III skin toxicity.
The median duration of radiation interruption because of patient inconvenience & machine technical issues were 3 & 5 days in the 1 st & 2 nd groups, respectively.
The median follow up was 22 (16 -24 months).
Acute Radiation Toxicity
As regard skin reaction, G1 was observed in 22 (44%) & 25 (50%) patients in group I & II respectively, G2 in 8 (16%) & 10 (20%) patients respectively, no G4 skin toxicity was detected. Radiation pneumonitis was observed in 2 patients (4%) only in group II, which developed 1.5 -2 months after the end of radiotherapy ( Toxicities   HFRT  CFRT  P value  I  II  III  IV  I  II  III IV   skin 
Survival
As regard survival in the HFRT & CFRT groups, the 2 year overall survival were 
Discussion
In breast cancer, radiotherapy is given to all patients after breast conservation and if indicated for patients after mastectomy [9] .
Adjuvant radiation therapy eradicates any tumor deposits remaining following surgery, which reduces locoregional recurrence (LRR) and improves breast Different hypofractionated schedules had been identified, one of the commonest hypofractionation protocols is 40 Gy/15 fractions/3 weeks, Therefore, this schedule leads to decrease in treatment time from 5 weeks to 3 weeks with nearly the same local control and cosmetic rate, also, it has more convenient and has financial advantages as it has lower costs due to fewer travels to treatment centers compared to conventional radiotherapy [10] .
Also, breast cancer radiation therapy is responsible for 25% -30% of all radiotherapy treatment burden. The hypofractionation regimen offers more efficient use of resources, so that more patients can be treated with the existing machines and personnel [11] .
The results of numerous randomized trials which compared conventional fractioned radiotherapy (50 Gy in 5 weeks/25 fractions) for patients with breast cancer with hypo fractionated radiotherapy (39 -42.9 Gy/13 -16 fractions in 3 -5 weeks) indicated that hypofractionation can be safely delivered to most patients [12] . So, the use of hypofractionation has gained increasing popularity as a post operative treatment following breast conservation [4] [7] [13] [14] , but the data on post-mastectomy hypofractionation is still limited. At our department, hypofractionation was first adopted as adjuvant treatment after breast conserving surgery in 2013, and then it has been increasingly used since then. Currently, almost all patients requiring adjuvant radiotherapy receive hypofractionation schedule (40 Gy/15 fractions/3 weeks). This trial was done to assess the efficacy and toxicity of hypofractionation schedule (40 Gy in 15 fractions) in post mastectomy breast cancer patients and to compare these results with those of post mastectomy patients treated retrospectively by conventional radiotherapy (50 Gy in 25 fractions) as regard OS, DFS and loco-regional control, and treatment toxicities.
In the current study, the 2 year overall survival were 96% & 94% respectively (p = 0.7), while the disease free survival were 91% & 89.8%, respectively (p = 0.9), and the LDFS were 95.8% & 93.3%, respectively (p = 0.9). As regard skin reaction, G1 was observed in 22 (44%) & 25 (50%) patients in group I & II respectively, G2 in 8 (16%) & 10 (20%) patients respectively, no G4 skin toxicity was detected. Radiation pneumonitis was observed in 2 patients (4%) only in group II.
Grade I dysphagia was observed in 21 (42%) & 18 (36%) cases in group I & II respectively, which improved by symptomatic treatment. G1 lymphedema was seen in 16 (32%) & 19 (38%) cases, G2 in 7 (14%) & 9 (18%) patients, respectively.
Several randomized trials that have proved equivalent local control and cosmosis between hypofractionation and conventional fractionation schedules [15] , [16] . ASTRO guidelines recommended hypofractionation use in early breast . START A trial is a multicenter randomized trial, involved 2236 patients with early breast cancer who received adjuvant hypofractionation schedules with 2 Gy (45 Gy/25 fractions) versus 3 Gy (39 Gy/13fractions) versus 3.2 Gy (41.6 Gy/13 fractions), the difference in 5 years locoregional relapse rates compared with 50 Gy were 0.2% after 41.6 Gy and 0.9% after 3.9 Gy [7] .
Also START B is a randomized trial involved 2215 early breast cancer patients who were given adjuvant radiotherapy by different schedules, 50 Gy/25 fractions at 2 Gy in 5 weeks versus 40 Gy/16 fractions at 2.67 Gy/3 weeks, locoregional tumor recurrence rates were comparable with slighty superior cosmetic outcome in hypofractionation group [4] .
The British Columbia randomized trial of adjuvant radiotherapy after mastectomy included 318 premenopausal women with node-positive disease, who were randomized to receive locoregional RT. Patients received 37.5 Gy in 16 fractions to the chest wall and 35 Gy in 16 fractions to the regional nodes, patients in the hypofractionated group had a lower incidence of loco-regional relapses (74% vs. 90%, p = 0.002) [20] .
Our Another retrospective study included breast cancer patients, who were treated by surgery, radiotherapy and adjuvant systemic therapy, radiotherapy was given by two schedules; conventional (162 patients), and hypofractionated (181 patients). The 4 year overall & disease free survival for the whole group were 86.5% & 83.8% respectively [23] .
A randomized trial involved postmastectomy breast cancer patients who were given 2 radiation schedules: Arm A (45) Arm B (46), 1 st arm was given 50 Gy/25 fractions and the 2nd was given 40 Gy/17 fractions. Chest wall recurrence was 5% versus 9% (p > 0.05), axillary lymph node failure 8% versus 7% (p > 0.05), distant metastasis 25% versus 28% (p > 0.05), no statistically significant difference in local control and efficacy was observed between the 2 radiation schedules [24] .
Forty-seven breast cancer patients (stage T2-4, any N), were randomized into Journal of Cancer Therapy 2 groups; conventionally fractionated group (N: 22), and hypofractionated group (N: 25). The 4year overall survival for the whole group were 98% (100% for CFRT group and 96% for HFRT group) (P = 0.37). The 4 year DFS for all patients were 87% (81% and 92% for CFRT and HFRT groups, respectively) (p = 0.47), regarding treatment toxicity, grade I skin toxicity were detected in55% and 52% of patients in the HFRT and CFRT groups, respectively, while grade II were 24% and 9.09%, respectively (p = 0.18). Grade II radiation pneumonitis were 12% & 4.5% in HFRT and CFRT groups, respectively. These results were comparable to the current study [25] .
In June 2004 and June 2012 were analyzed, they were treated by hypofractionated radiotherapy (HFRT) whether, after breast conservation (116/57%) or mastectomy (43/89%). Three out of 116 (2.6%) patients and 4/89 (4.5%) had local relapse after breast conserving surgery and mastectomy, respectively. Five year local recurrence rate was 4.4%. grade III skin toxicity was detected in (8/4.5%) patients, late fibrosis in (29/14%) and telangiectasia (16/8%), with no pulmonary or cardiac toxicities [28] . In a prospective study, 56 patients treated by adjuvant HFRT (42.5 Gy/16 fractions in 3 weeks). Acute dermatitis of grade I, II and III were detected in 75%, 16% and 1.8%, respectively. Radiotherapy was not interrupted for any patient [29] .
Two hundred and sixteen breast cancer patients following mastectomy were treated with 2 hypofractionated schedules: 40 Gy/15 sessions or 42.5 Gy/16 sessions, 14.8% developed ≥ Grade (Gr) 2 late cardiac toxicity, 10.2% developed ≥ Gr2 late pulmonary toxicity. There were 28.7% patients who developed ≥ Gr2 lymphedema. Sixty-seven out of 216 patients had symptomatic brachial plexopathy at 5-year follow-up [30] .
In a phase II trial by Khan et al., patients with stage II to IIIa breast cancer were treated by postmastectomy hypofractionated radiation, in 15 fractions, they F. M. F. Akl, A. Khater stated that it was tolerable and efficient in patients. Acute dermatitis was the commonest (24%) toxicity, then, fatigue (7.5%), pain (4.5%), and lymphedema (4.5%). Chest wall recurrence was detected in 2 patients (3%). the 3 year LRFS was89.2%, while distant recurrence free survival was 00.3 [31] .
The current results are consistent with most of mentioned trials.
Conclusion
Post-mastectomy hypofractionated radiation therapy achieved comparable OS, DFS, LDFS and toxicity to the conventionally fractionated radiotherapy with the advantage of reducing overall treatment time, treatment burden & cost.
Limitations
This study is limited by the relatively small number of patients and short follow-up period and the retrospective nature of the control group.
